


| | | | | |
|--|-------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICATION NO.: 10/725,952 | | ATTY. DOCKET NO.: 10248.70015US01 | |
| | FILING DATE: December 1, 2003 | | CONFIRMATION NO.: 3968 | |
| | APPLICANT: Bachovchin et al. | | | |
| | GROUP ART UNIT: 1631 | | EXAMINER: Michael L. Borin | |
| Sheet 1 of 4 | | | | |

U.S. PATENT DOCUMENTS

| Examiner's Initials | U.S. Patent Document No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|------------------------|-----------------------------|----------------------|-----------|---|--|
| | | Number | Kind Code | | |
| MB | A92 | 5,580,486 | | Labeque et al. | 12-03-1996 |
| | A93 | 5,780,454 | | Adams et al. | 07-14-1998 |
| | A94 | 6,319,893 | | Demuth et al. | 11-20-2001 |
| | A95 | 6,890,898 | B2 | Bachovchin et al. | 05-10-2005 |
| | A96 | 7,067,489 | B2 | Wallner et al. | 06-27-2006 |
| | A97 | 2001-0020006 | A1 | Demuth et al. | 09-06-2001 |
| | A98 | 2002-0049164 | A1 | Demuth et al. | 04-25-2002 |
| | A99 | 2002-0071838 | A1 | Demuth et al. | 06-13-2002 |
| | A100 | 2002-0082427 | A1 | Demuth et al. | 06-27-2002 |
| | A101 | 2002-0110560 | A1 | Demuth et al. | 08-15-2002 |
| | A102 | 2002-0198242 | A1 | Demuth et al. | 12-26-2002 |
| | A103 | 2003-0125304 | A1 | Demuth et al. | 06-03-2003 |
| | A104 | 2003-0148961 | A1 | Heiser et al. | 08-07-2003 |
| | A105 | 2004-0043919 | A1 | Von Horsten et al. | 03-04-2004 |
| | A106 | 2004-0171555 | A1 | Demuth et al. | 09-02-2004 |
| | A107 | 2005-0043299 | A1 | Evans et al. | 02-24-2005 |
| | A108 | 2005-0070459 | A1 | Bachovchin et al. | 03-31-2005 |
| | A109 | 2005-0070482 | A1 | Bachovchin | 03-31-2005 |
| | A110 | 2006-0287245 | A1 | Wallner et al. | 12-21-2006 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|------------------------|-------------|-------------------------|----------|--------------|--|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | B48 | WO | 97/40832 | A1 | Hans-Knöll-Institut für Naturstoff-Forschung | 11-06-1997 | Y-Abstract |
| | B49 | WO | 99/38501 | A2 | Trustees of Tufts University | 08-05-1999 | |
| | B50 | WO | 99/46272 | A1 | Fondatech Benelux N.V. | 09-16-1999 | |
| | B51 | WO | 99/61431 | A1 | Probiobrug Gesellschaft für Arzneimittelforschung MBH | 12-02-1999 | Y-Abstract |
| | B52 | WO | 99/67278 | A1 | Pro-Biodrug Gesellschaft für Arzneimittelforschung MbH | 12-29-1999 | Y-Abstract |
| MB | B53 | WO | 01/98468 | A2 | Incyte Genomics, Inc. | 12-27-2001 | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 05/09/07 |


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|--|---|----|---|-------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/725,952 | | ATTY. DOCKET NO.: 10248.70015US01 | |
| | | | | FILING DATE: December 1, 2003 | | CONFIRMATION NO.: 3968 | |
| | | | | APPLICANT: Bachovchin et al. | | | |
| | | | | GROUP ART UNIT: 1631 | | EXAMINER: Michael L. Borin | |
| Sheet | 2 | of | 4 | | | | |

| | | | | | | | |
|----|-----|----|-------------|----|---|------------|--|
| MB | B54 | WO | 03/045228 | A2 | Trustees of Tufts College, Brigham and Women's Hospital | 06-05-2003 | |
| | B55 | WO | 03/045977 | A2 | Trustees of Tufts College | 06-05-2006 | |
| | B56 | WO | 03/092605 | A2 | Trustees of Tufts College | 11-13-2003 | |
| | B57 | WO | 2005/082348 | A2 | Trustees of Tufts College | 09-09-2005 | |
| | B58 | WO | 2005/106487 | A1 | Bayer Healthcare Ag | 11-10-2005 | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS


| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|-----------------------|---------|---|-------------------|
| | C143 | ABBOTT et al., Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett. 1999 Sep 24;458(3):278-84. | |
| | C144 | ABBOTT et al., Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000 Oct;267(20):6140-50. | |
| | C145 | AHN et al., Pyrazolidine derivatives with heteroaryl urea as dipeptidyl peptidase IV inhibitors. Chem Pharm Bull (Tokyo). 2005 Aug;53(8):1048-50. | |
| | C146 | ANSORGE et al., Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system. Acta Histochem. 1987;82(1):41-6. Abstract Only. | |
| | C147 | AOYAGI et al., Multiple enzymes related to differentiation of lymphocyte subpopulations in man. Biochem Int. 1989 Feb;18(2):383-9. | |
| | C148 | AYTAC et al., Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res. 2001 Oct 1;61(19):7204-10. | |
| | C149 | BENSAADI et al., Modulation of enzymatic activities during spontaneous and induced differentiation in a human pancreatic adenocarcinoma cell line CAPAN-1. Int J Pancreatol. 1989 May;4(4):391-406. Abstract Only. | |
| | C150 | BODUSZEK et al., Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J Med Chem. 1994 Nov 11;37(23):3969-76. | |
| | C151 | BRANDT et al., Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-[[(3-hydroxyadamantan-1-yl)amino]acetyl]-pyrrolidine-2-carbonitrile). Biochem Pharmacol. 2005 Jul 1;70(1):134-43. Abstract Only. | |
| | C152 | BRUBAKER et al., Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am Phys Soc. 1997:E1050-8. | |
| | C153 | BUSEK et al., Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004 Mar;36(3):408-21. | |
| | C154 | CHEN et al., Dipeptidyl peptidase IV gene family. The DPIV family. Adv Exp Med Biol. 2003;524:79-86. | |
| MB | C155 | DANG et al., 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol. 1991 Nov 1;147(9):2825-32. Abstract Only. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 05/09/07 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | | | |
|--|---|----|---|-------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/725,952 | | ATTY. DOCKET NO.: 10248.70015US01 | |
| | | | | FILING DATE: December 1, 2003 | | CONFIRMATION NO.: 3968 | |
| | | | | APPLICANT: Bachovchin et al. | | | |
| | | | | GROUP ART UNIT: 1631 | | EXAMINER: Michael L. Borin | |
| Sheet | 3 | of | 4 | | | | |

| | | | |
|------|------|--|--|
| 1717 | C156 | DANG et al., Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol. 1990 Jun 1;144(11):4092-100. Abstract Only. | |
| | C157 | DEACON et al., Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998 May;47(5):764-9. | |
| | C158 | DONG et al., Role of CD26 for CD4 memory T cell function and activation. Hum Cell. 1996 Sep;9(3):153-62. Abstract Only. | |
| | C159 | DRUCKER et al., Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997 Jul;15(7):673-7. | |
| | C160 | DRUCKER et al., Glucagon-like peptides. Diabetes. 1998 Feb;47(2):159-69. | |
| | C161 | EDOSADA et al., Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 2006 Mar 6;580(6):1581-6. | |
| | C162 | EDOSADA et al., Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem. 2006 Mar 17;281(11):7437-44. Epub 2006 Jan 12. | |
| | C163 | FLEISCHER et al., CD26: a surface protease involved in T-cell activation. Immunol Today. 1994 Apr;15(4):180-4. Abstract Only. | |
| | C164 | GIBSON et al., A practical synthesis of L-Valyl-pyrrolidine-(2R)-boronic acid: Efficient recycling of the costly chiral auxiliary (+)-pinanediol. Org Proc Res & Dev. 2002;6:814-6. | |
| | C165 | GORRELL et al., Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005 Apr;108(4):277-92. | |
| | C166 | GUTHEIL et al., Kinsq: a program for fitting kinetics data with numerically integrated rate equations and its application to the analysis of slow, tight-binding inhibition data. Anal Biochem. 1994 Nov 15;223(1):13-20. Abstract Only. | |
| | C167 | GUTHEIL et al., Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6594-8. | |
| | C168 | HAFLE et al., Mechanisms of immune memory. T cell activation and CD3 phosphorylation correlates with Ta1 (CDw26) expression. J Immunol. 1989 Apr 15;142(8):2590-6. Abstract Only. | |
| | C169 | HEYMANN et al., A negative blood-clotting factor lining the vessels. Naturwissenschaften. 1982 Apr;69(4):189-91. | |
| | C170 | HEYMANN et al., Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 1978 Jul 15;91(2):360-4. | |
| | C171 | HILDEBRANDT et al., Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol. 2001 Oct;36(10):1067-72. Abstract Only. | |
| | C172 | HUGHES et al., NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine], a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry. 1999 Sep 7;38(36):11597-603. | |
| | C173 | KIEFFER et al., Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995 Aug;136(8):3585-96. | |
| 1717 | C174 | MENTLEIN et al., Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35. Abstract Only. | |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
|  | 05/09/07 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|--|---|----|---|-------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/725,952 | ATTY. DOCKET NO.: 10248.70015US01 |
| | | | | FILING DATE: December 1, 2003 | CONFIRMATION NO.: 3968 |
| | | | | APPLICANT: Bachovchin et al. | |
| | | | | GROUP ART UNIT: 1631 | EXAMINER: Michael L. Borin |
| Sheet | 4 | of | 4 | | |

| | | | |
|-------------|------|---|--|
| <i>12/1</i> | C175 | MORRISON et al., A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med. 1993 Apr 1;177(4):1135-43. | |
| | C176 | OGATA et al., Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J Biol Chem. 1989 Feb 25;264(6):3596-601. | |
| | C177 | PETHIYAGODA et al., Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin Exp Metastasis. 2000;18(5):391-400. Abstract Only. | |
| | C178 | REINHOLD et al., The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem. 2002 Jul-Aug;383(7-8):1133-8. | |
| | C179 | ROTELLA et al., Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest. 2005 Sep;28(8):746-58. Abstract Only. | |
| | C180 | TORIMOTO et al., Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 1991 Oct 15;147(8):2514-7. Abstract Only. | |
| | C181 | VIVIER et al., Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol. 1991 Jul 15;147(2):447-54. Abstract Only. | |
| | C182 | WEBER et al., Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004 Aug 12;47(17):4135-41. | |
| | C183 | YAMADA et al., A potent dipeptide inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1537-40. | |
| <i>12/1</i> | C184 | ZHAO et al., Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg Med Chem. 2003 Jan 17;11(2):207-15. | |

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|--------------------|------------------|
| EXAMINER: | DATE CONSIDERED: |
| <i>[Signature]</i> | <i>05/09/07</i> |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.